Skip to content

Brain development between ages 8 and 25: A longitudinal study

Brain development between ages 8 and 25: A longitudinal study - BDC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41665
Enrollment
280
Registered
2010-12-17
Start date
2011-02-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GEEN AANDOENING! gezonde hersontwikkeling: hersenfunctie, hersenstructuur en gedrag n.a.

Interventions

None listed

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: See also page 20 in the protocol 1. Healthy children, adolescents and young adults without a history of neurological disorders 2. Right-handed 3. No counter-indications for MRI 4. Native Dutch speakers

Exclusion criteria

Exclusion criteria: 1. Lefthanded 2. A history of psychiatric and/or neurological disorders 3. Counter-indications for MRI (such as metal implants, heart arrhythmia, claustrophobia, and possible pregnancy

Design outcomes

Primary

MeasureTime frame
The MRI-scans: 1. Structural MRI, to gain information on gray and white matter properties (volume, density and cortical thickness) 2. DTI, to gain specific information on white matter microstructure and fibertracking 3. Functional MRI, to gain information on task-related brain activity during cognitive and emotional decisionmaking. Pubertal assessment: 1. Participants will be asked to complete three self-report measures of pubertal maturation. The self-report scales are 1) the picture-based interview about puberty (PBIP), 2) the Tanner scale, and 3) the Pubertal Development Scale (PDS: Petersen et al., 1988 2. Participant will be asked to provide saliva and urine samples to test for testosterone, DHEA, progesterone, estradiol and luteinizing hormone (LH; the earliest hormonal marker of puberty) levels. Genes 1. Genetic information will be measured using an easy cheek swab method.

Secondary

MeasureTime frame
See above

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)